drugset / Trial / NCT07452198
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
Timeline
- Start
- 2026-03-09
- Primary completion
- 2029-03
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |
| Subject | GR1803 | Unknown | 180 ug/kg | Intravenous |
| Comparator | Dexamethasone | Small molecule | 20 mg | — |
| Comparator | Dexamethasone | Small molecule | 40 mg | — |
| Comparator | Pomalidomide | Other / unclassified | 4 mg | — |